← Eichor
Condition: Refractory Systemic Lupus Erythematosus Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Systemic Lupus Erythematosus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MB-CART19.1 in Refractory SLE
Phase 1/Phase 2 · 3 location(s) · Miltenyi Biomedicine GmbH · NCT06189157UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT07109986Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07031713A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06897930Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
Phase N/A · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07352332An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06920433Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT06934447Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune D
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07558850CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07470151Alnuctamab for Refractory SLE (LATTE Study)
Phase 1 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT07219563Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06946485Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06056921Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06585514Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
Phase 1 · 2 location(s) · Mao Jianhua · NCT06789107Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497387Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
Phase 1 · 2 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06892145Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
Phase 1 · 1 location(s) · National University of Malaysia · NCT06710717Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
Phase 3 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06904729Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT06010472Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Phase 1 · 2 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06400537Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
NA · 1 location(s) · Anhui Provincial Hospital · NCT07121777Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07331467
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.